Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma

2.1 Tafasitamab (Minjuvi, Incyte) is indicated, in combination with lenalidomide followed by tafasitamab monotherapy, for 'the treatment of adult patients with relapsed or refractory diffuse large B‑cell lymphoma who are not eligible for autologous stem cell transplant'.

2.2 The dosage schedule is available in the summary of product characteristics for tafasitamab.

2.3 Tafasitamab costs £705 per 200‑mg vial of powder for concentrate for solution for infusion (excluding VAT; company submission). Tafasitamab costs £120,639 for 12 months of treatment in year 1 and £95,049 for year 2 onwards. The list price of lenalidomide per 21‑capsule pack varies according to capsule size: £3,426.00 (2.5 mg), £3,570.00 (5 mg), £3,675.00 (7.5 mg), £3,780.00 (10 mg), £3,969.00 (15 mg), £4,168.50 (20 mg) and £4,368.00 (25 mg; all prices excluding VAT; BNF online accessed February 2023).

2.4 The company has a commercial arrangement for tafasitamab, which would have applied if the technology had been recommended. There is a nationally available discount for lenalidomide with the Commercial Medicines Unit. The prices agreed through the framework are commercial in confidence.